Epilepsy

The submission includes findings from Study 1601, along with long-term safety and efficacy data from Zogenix’s ongoing open-label extension trials.

Despite not achieving statistical significance, there was greater relative reduction in seizure frequency over placebo in those with a structural etiology for focal epilepsy than those without, laying the foundation for future research.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 24, 2021.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending September 18, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 17, 2021.

The director of the division of vascular neurology at the University of Utah discussed ongoing efforts from the AAN, as well as the potential to integrate advanced practice providers into neurology teams.

Longboard Pharmaceuticals plans to initiate a phase 1b/2a trial to determine the efficacy of the 5-HT2c receptor superagonist in patients with developmental and epileptic encephalopathies.

The division chief of vascular neurology at the University of Utah discussed the misperceptions surrounding the field of neurology, as well as the importance of increasing fellowship training.

The division chief of vascular neurology at the University of Utah discussed the driving force behind the national shortage of neurologists and its effect on patient care.

Here's what is coming soon to NeurologyLive.

Jennifer Majersik, MD, MS, commented on how the AAN, as well as current neurologists and specialists, can help generate interest in the field of neurology to meet patient needs.

Persons with epilepsy younger than 50 years had a 34-fold increased risk of sudden unexplained death compared with persons without epilepsy.

Jennifer Majersik, MD, MS, division chief of vascular neurology at the University of Utah, discussed contributing factors to the neurologist shortage, as well as ongoing efforts to increase interest in the field.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 10, 2021.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

Peter Crino, MD, and Steven Roberds, PhD, join NeurologyLive to discuss several topics regarding the state of care for tuberous sclerosis complex, and the future of and advances in research.

Here's what is coming soon to NeurologyLive.

The 50% responder rate was 58.3% at 12 months and 50.0% at the last visit, with corresponding seizure freedom rates of 23.2% and 20.5%, respectively.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 3, 2021.

Davis offered comments on the recent approval of brivaracetam (Birviact; UCB) as a treatment for pediatric patients with partial-onset seizures and its potential for these patients.

The web-implemented algorithm misclassified and misdiagnosed seizures in only 16.8% of the patients with epilepsy—lower than rates previously reported in the literature.

After receiving original approval in 2016, brivaracetam is now available as both monotherapy or adjunctive therapy to treat partial-onset seizures in pediatrics 1 month of age and older.

Here's what is coming soon to NeurologyLive.